CBI2026 Antibody Drug Development Conference: Secure 1-on-1 Meetings with Top Decision-Makers from Innovent, Huaontai, Excalipoint, BeiGene, and Sanofi
BeOne
Developer of Molecular Targeted and Immune Anti-Tumor Drugs
Bispecific antibody deal volumes continue to hit record highs, as the battlefield for antibody therapeutics rapidly expands from oncology into multi-billion-dollar markets such as autoimmune diseases, chronic conditions, and cardiovascular disorders. From differentiated bispecific antibody development and early-stage translation strategies to CMC scale-up and commercialization, competition in the antibody drug sector has entered a new phase defined by end-to-end capabilities.
September 4-5, 2026[CBI2026 Biopharmaceutical Innovation Expo — Antibody Drug Development Conference]The event will be held in Hall B, Room 106 of the Suzhou International Expo Center. The conference features three thematic sessions: Innovation in Bispecific Antibody Drugs, Translational Strategies for Early-Stage Antibody Drug R&D, and CMC Development Strategies for Antibody Drugs. It brings together senior industry experts to engage in in-depth discussions on differentiated development, translational medicine, and industrialization. Free registration is welcome!
First-Come, First-Served Benefit: Share this article to your WeChat Moments and keep it visible for 24 hours. Contact the QR code assistant with a screenshot to register, and you will receive one complimentary business lunch voucher for the conference! Enjoy both the exhibition and your meal—share now!
Forum Name:CBI 2026 Antibody Drug Development Conference
Forum Schedule:September 4–5, 2026
Forum Location:Hall B, Booth B106, Suzhou International Expo Center
September 5
Translational Strategies in the Early Development of Antibody Drugs
[ Co-Planner ]
Wen Danyi, Founder, Chairman and CEO of Shanghai Lidi Biology
◈ 09:30-09:50
Subject Confirmation in Progress
Guest itinerary under confirmation
◈ 09:50-10:10
Subject Confirmation in Progress
Shen Yu
BeOne, Head of Biology
◈ 10:10-10:30
Application of QSP Modeling in the Context of the China-US Pioneer Program: A Case Study on Clinical Translation Decision-Making for Bispecific Antibodies and Multi-Target Drugs
Zhao Chen
Professor, Doctoral Supervisor, and Chair of the Department of Clinical Quantitative Pharmacology at Nanjing Medical University
◈ 10:30-10:50
Subject Confirmation in Progress
Fang Lei
Ecolink Biotechnology, Co-Founder, Chairman & CEO
◈ 10:50-11:10
Biobank-Based Discovery of Drug-Resistance Targets and Antibody Drug Intervention
Xie Bin
Lead Biology, Vice President of R&D and Head of Tumor Immunology
◈ 11:10-11:30
Subject Confirmation in Progress
Xiao Tengfei
Xun Baihui Biotech, CTO
◈ 11:35-12:20
Panel: Breaking the Impasse in Bispecific Antibody Development for Solid Tumors
[ Host ]
Wen DanyiShanghai Lidi Biotech, Founder, Chairman and CEO (Moderator)
[ Guest ]
Li BinHengrui Medicine, Head of Preclinical Development and Translational Medicine
Chen BingliangInnovent Biologics, Chief Scientist
Guo BingshiJiyu Pharma, Head of Biologics R&D
Gao ChangshouAllist Pharmaceuticals, CTO
Zhu XiangyangHuaaoTai Biologics, CEO
Zhou LingIntrepide/Sanofi, Head of R&D in Suzhou
◈ 12:20-13:30
Lunch Break
Scan the QR Code to Register Now
Scan the QR Code to Register Now
Step 1:Click [Sign Up Now] in the lower-right corner. After successful registration, click the [<] back button in the upper-left corner to return to the main screen.
Step 2:Select the "1v1 Appointment" page on the registration mini-program.
Step 3:Click the “Guest” tab and select the guest you wish to link from the guest list.
Step 4:Fill out the appointment form and wait for confirmation after submission.
Note: The appointment system isReview System,The right to interpret the review criteria is reserved by the organizer.
PharmaCircle × PharmaCircle Industrial Research Institute,Leveraging over a decade of in-depth industry expertise, we are proud to unveil the 2026 White Paper Series covering seven key sub-sectors, to be officially released at the 8th China Pharmaceutical Manufacturing Expo (CMC Pharma Expo) on September 4–5.White Paper on the Development of China's Innovative Drug Industry in 2026By aggregating vast amounts of real-world industry data, case studies from leading enterprises, competitive landscape analyses, and comparisons of domestic and international policies, this publication provides authoritative data support and decision-making references for innovative pharmaceutical companies in project initiation and therapeutic area selection, CXO firms in market positioning, investment institutions in project due diligence, and pharmaceutical industrial parks in investment promotion planning. It is an indispensable annual industry reference for professionals in new drug R&D, corporate decision-makers, and industry investors.
Cover Contents ↓
Registration Method: Scan the QR Code to Register“CBI2026 Biomedical Innovation Expo”+ Repost this article to your WeChat Moments to claim it at the conference venue in Suzhou International Expo Center on September 4–5. (Limited quantity; available on a first-come, first-served basis).
Scan the QR code to register now
Registration:
ConferenceLimited-Time Free Access(Subject to capacity limits; registration is on a first-come, first-served basis. This is a pre-registration; registration is confirmed only upon approval of the application.) Attendees are responsible for their own accommodation and meals.
